Search | Page 15 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Therapies

    ... low- and high-risk patients with all sub-types of MDS. Lenalidomide (Revlimid®) is approved for transfusion-dependent MDS ...

    Page last updated 03/18/2016 - 11:26am.

  2. PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

    ... initiating treatment in this study with the exception of lenalidomide , decitabine , azacitidine , imatinib mesylate, ...

    Clinical Trial last updated 04/29/2016 - 3:09pm.

  3. Nursing Education Modules on MDS Disease Management and Patient Education

    ... Treatment options for low-risk MDS – observation, EPO, lenalidomide , immune suppression,       iron chelation Treatment ...

    Page last updated 04/27/2015 - 2:44pm.

  4. Incidence and Burden of the Myelodysplastic Syndromes

    ... even though treatments such as azacitidine and lenalidomide have been shown to decrease red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:11am.

  5. Myelodysplastic syndromes: What do hospitalists need to know?

    ... are offered erythropoiesis-stimulating agents (ESAs), lenalidomide , and immununosuppressive therapy.  ESAs are injections ... risk of blood clots in MDS unlike in other malignancies.  Lenalidomide (Revlimid®) has been used primarily in patients with a ...

    Research Review last updated 05/02/2016 - 9:21am.

  6. Clinical Trial Basics

    ... (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) ...

    Page last updated 03/29/2016 - 7:29pm.

  7. Amer Zeidan, M.D.

    ... and his colleagues confirmed the clinical benefits of lenalidomide and iron chelation therapy in patients with MDS at the ...

    Bio last updated 03/11/2016 - 1:41pm.

  8. FAQs

    ... bone marrow cells. These therapies currently include lenalidomide (Revlimid), decitabine (Dacogen) and azacitidine ... active treatments currently available. These include lenalidomide (Revlimid®) decitabine (Dacogen®) and ...

    Topic section last updated 03/02/2016 - 11:42am.

  9. Nurse's Corner Summer 2015: Understanding the Etiology and Epidemiology of Myelodysplastic Syndromes

    ... Available options include erythroid stimulating agents, lenalidomide for patients with deletion 5 q MDS, hypomethylating agents and ...

    Page last updated 07/27/2015 - 12:04pm.

  10. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... demethylating agents (azacytidine or decitabine , lenalidomide , etc) ALLOWED. Cohort B: Patients who have received prior ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.